ESTRADIOL AND NORETHINDRONE ACETATE

Post-LOE

estradiol and norethindrone acetate

Aurobindo Pharma

ANDAORALTABLET

Approved

Feb 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ESTRADIOL AND NORETHINDRONE ACETATE (estradiol and norethindrone acetate) by Aurobindo Pharma is estrogen receptor agonists [moa]. Approved for moderate to severe vasomotor symptoms due to menopause (1, moderate to severe symptoms of vulvar, vaginal atrophy due to menopause (1 and 4 more indications. First approved in 2018.

Drug data last refreshed 18h ago

Mechanism of Action

Estrogen Receptor Agonists

Pharmacologic Class:

Estrogen

Indications (6)

Moderate to Severe Vasomotor Symptoms due to Menopause (1 Moderate to Severe Symptoms of Vulvar

Worked on ESTRADIOL AND NORETHINDRONE ACETATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.